Bris­tol My­er­s' CAR-T Breyanzi hits end­points in two lym­phoma stud­ies

Bris­tol My­ers Squibb is tout­ing promis­ing da­ta for its block­buster CAR-T Breyanzi in two lym­phoma clin­i­cal tri­als.

The com­pa­ny said Mon­day that the ther­a­py met the pri­ma­ry end­point of over­all re­sponse rate and a sec­ondary end­point of com­plete re­sponse rate in both a Phase I and a sep­a­rate Phase II tri­al. Bris­tol My­ers not­ed that no new safe­ty sig­nals were re­port­ed.

The Phase I study, a piv­otal tri­al called TRAN­SCEND NHL 001, is an open-la­bel and sin­gle-arm tri­al in­ves­ti­gat­ing Breyanzi in pa­tients with five dif­fer­ent types of non-Hodgkin lym­phomas. The com­pa­ny said over­all re­sponse rate was met in the sub­set of pa­tients with man­tle cell lym­phoma. Ear­li­er this year, Eli Lil­ly’s BTK in­hibitor Jaypir­ca re­ceived FDA ap­proval for pa­tients with re­lapsed or re­frac­to­ry man­tle cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER